McKesson

McKesson Canada - McKesson

Pharmaceutical company

About INVIVA
Established in 2013, today INVIVA is Canada's largest private infusion network with 68 clinics that provide patients with specialized therapy in a caring and compassionate setting. INVIVA experts work directly with manufacturers to bring specialty therapies and nursing services to patients in need while improving access. They engage with health care providers to improve the patient experience and make it easier for everyone to manage complex diseases. Its team of highly trained seasoned nurses help manage various therapeutic areas, including gastroenterology, rheumatology, geriatrics, pediatrics, and more. In 2023, INVIVA was awarded accreditations in Cancer Care, Ambulatory Care, Home Care Services, Leadership, Infection Prevention and Control, and Medication Management making it the first national private infusion network with accreditation.
About McKesson Canada
McKesson Canada is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of healthcare at.
Media contact:
Sybil Millar Senior Advisor, Media Relations and External Communications, McKesson Canada
"By offering radioligand therapy at INVIVA, we are expanding access to this transformative treatment for patients across the province, while also reinforcing our commitment to advancing patient care, " says Dimitris Polygenis, President, Specialty Health, McKesson Canada.
Radioligand therapy represents a breakthrough in nuclear medicine, offering a targeted approach that can significantly improve outcomes for patients with various forms of cancer. By delivering radiation directly to cancer cells, RLT minimizes impact on healthy tissue, resulting in a more precise and effective treatment.
The organization has invested extensively in the infrastructure and certification needed to deliver nuclear medicine safely and effectively. Staff have undertaken comprehensive training, and the clinic has been licensed by the Canadian Nuclear Safety Commission (CNSC), which requires adherence to rigorous quality assurance standards.
Ensuring comprehensive, timely and equitable access to medication for rare diseases is a significant public policy priority for the Government of Canada. McKesson Canada is proud to contribute to the public policy conversation around this national strategy, building on its experience with patient support programs, pharmaceutical distribution, and specialty pharmacy services.